 1. Primary Objectives Safety run-in - To determine the safety of SABR for the treatment of primary lung disease and N1 hilar node in stage T1-2a N1 NSCLC Phase II - To determine 2-year local control of SABR for T1-2a N1 NSCLC with sequential chemotherapy 